Welcome to the QIAGEN Cancer Research Community for dedicated and passionate cancer researchers. We are working to conquer cancer with an emphasis on collaborating together worldwide to share knowledge, materials, methods and data to enable breakthroughs in cancer research.
Choose from the bundles below and you will be directed straight to your cart.
|Free product||Cat. no.||+||Purchased product||Cat. no.|
|exoRNeasy Serum/Plasma Starter Kit (20)||77023||QIAamp MinElute ccfDNA Mini Kit (50)||55204||ADD BUNDLE|
|AdnaTest CTC-Select||395092||ADD BUNDLE|
Contact your QIAGEN Customer Care Team and include "ELIMA bundle" in the body of your order.
In this live discussion with QIAGEN research experts, we will summarize the findings of the ELIMA study that have been described in detail in the podcast and science talks over the course of this Cancer Insights Session. We will also look at each part of the workflow for analyzing extracellular vehicles, circulating tumor cells and cfDNA in parallel, and the tools we can use for further analysis of the data. This will include targeted DNA sequencing using UMIs, bioinformatics solutions, targeted methylated-DNA sequencing, miRNA sequencing and simultaneous DNA and RNA profiling by NGS. We will put a spotlight on collection and stabilization of blood samples to enable multianalyte approaches in liquid biopsy and will discuss the need for standardization of methods for validation of biomarkers from basic research to clinical research – standardization is key. Throughout the discussion you will be invited to ask questions using the chat function, or you can ask questions in advance by email.
Abstract: Cancer patients are usually treated according to the so-called predictive markers on their primary tumors. However, these markers can change during the molecular evolution of distant metastases, finally leading to death. Primary tumor tissue is only available at the time of first diagnosis and metastatic tissue is often difficult to obtain. Even if accessible, a single tumor biopsy is mostly a single snapshot in time and does not always mirror the characteristics of the disease, mostly due to the known heterogeneity of individual lesions. In this regard, the use of biological fluids such as blood as a non-invasive source of cellular and nucleic acid biomarkers would be an ideal "surrogate tissue" to identify and monitor prognostic and predictive factors that will help in selecting the optimal therapeutic strategy for each individual patient. We approached this challenge and compared and analyzed, all from one blood sample, RNA profiles enclosed in circulating tumor cells or extracellular vesicles and performed mutational analysis of cell-free DNA (cfDNA) in plasma samples (next-generation sequencing) in the follow up of the disease to get insights into their feasibility for therapy stratification and to predict therapeutic options.
Abstract:Cancer patients are usually treated according to the so-called predictive markers on Blood analytes as liquid biopsies, are discussed to be surrogate markers for therapy stratification. Furthermore, the analysis of RNA enclosed in circulating tumor cells (CTCs) or extracellular vesicles (EVs) may be sensitive enough to detect disease progression earlier than contemporary visual staging methods. Repeated analysis is enabled by the minimal invasive nature of blood draw. Here we compared RNA profiles of CTCs and EVs in metastatic breast cancer (MBC) patients to get insights about their feasibility for therapy stratification.
Expression profiling in CTCs as well as in EVs is enabled by the described workflows and may be an alternative for therapy monitoring. Data indicated great differences in RNA profiles of EVs and CTCs.
Abstract:Blood analytes are discussed to be surrogate markers for therapy stratification, as serial sampling enabled by the minimal invasive nature of blood draw facilitates monitoring of clonal evolution. Cell-free DNA (cfDNA) is described to mirror intra-tumoral heterogeneity and gives insights about clonal evolution for improved therapeutic decisions. We sequenced cfDNA of a hormone receptorpositive, HER2-negative metastatic breast cancer (MBC) cohort with a high coverage to examine the prevalence and relevance of any detected variant.
Unique molecular identifiers enable the identification of true positive mutations in cfDNA. The identification of new variants with high prevalence, prognostic value, and dynamics under treatment by deep sequencing of cfDNA might empower sensitive monitoring and personalized therapeutic decisions in the future.
Abstract:Liquid biopsy analytes such as cell-free DNA (cfDNA) and circulating tumor cells (CTCs) exhibit great potential for personalized treatment. Since cfDNA and CTCs are considered to give additive information and blood specimens are limited, isolation of cfDNA and CTC in an “all from one tube” format is desired. We investigated whether cfDNA variant sequencing from CTC-depleted blood impacts the results compared to cfDNA variant sequencing from matched whole blood (WB).
We present a feasible workflow for CTC and ctDNA evaluation for expression and mutation analysis from the same blood sample. Matched cfDNA mutational and CTC transcriptional analyses might empower a comprehensive liquid biopsy analysis to enhance the identification of actionable targets for individual therapy strategies of MBC patients in the future.
* This offer is valid until May 4, 2020 and only when order is placed online through QIAGEN web shop, your organization’s purchasing system, your sales rep, or by email using the ELIMA promo code. Offer only applies to selected products listed above and is available only to registered members of the QIAGEN Cancer Research Community. Offer not valid in all countries. Offer is subject to availability of products in respective countries. Offer may not be combined with any other promotions. Void where prohibited. It is the customer's responsibility to ensure that acceptance of this offer will not violate any internal policies of their organization. Offer limited to one order per person. Products in offer are for use in molecular biology research applications only. Not for use in diagnostic procedures.+ QIAGEN products shown here are intended for molecular biology applications. These products are not intended for the diagnosis, prevention or treatment of a disease.